RNA Covid vaccine was initially 'developed for oncology use and was already in phase 2'

A new treatment nearly halves the risk of disease progression or death from a less common form of breast cancer that hasn’t seen major drug advances in over a decade, Results from the study, presented at the annual meeting of the American Society for Clinical Oncology and could soon establish a new first-line therapy for people with HER2-positive metastatic breast cancer. Meanwhile, researchers are combining RNA and AI to develop tailor-made vaccines to combat cancer. For a deeper understanding of new technological breakthroughs in medicine, FRANCE 24’s François Picard welcomes Dr. Moez Benali, Oncology Global Senior Medical Director of Clinical Development and Global Head of Medical Affairs at Labcorp.